Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ficerafusp Alfa,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Morgan Stanley
Deal Size : $362.0 million
Deal Type : Public Offering
Bicara Therapeutics Closes $362M IPO with Full Exercise of Underwriters' Option
Details : The net proceeds from the financing will be used to support the development of BCA101 (ficerafusp alfa) a first-in-class, bifunctional EGFR/TGF-β antibody for head and neck squamous cell carcinoma.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 16, 2024
Lead Product(s) : Ficerafusp Alfa,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Morgan Stanley
Deal Size : $362.0 million
Deal Type : Public Offering
Lead Product(s) : Ficerafusp Alfa,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Morgan Stanley
Deal Size : $315.0 million
Deal Type : Public Offering
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering
Details : The net proceeds from the financing will be used to support the development of BCA101 (ficerafusp alfa) a first-in-class, bifunctional EGFR/TGF-β antibody for head and neck squamous cell carcinoma.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 12, 2024
Lead Product(s) : Ficerafusp Alfa,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Morgan Stanley
Deal Size : $315.0 million
Deal Type : Public Offering
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bicara Reports Updated Data for Ficerafusp Alfa in HPV-negative Head and Neck Cancer
Details : BCA101 (ficerafusp alfa), a first-in-class bifunctional EGFR/TGF-β inhibitor, investigated for frontline HPV-negative, R/M HNSCC, advanced squamous NSCLC and cutaneous squamous cell carcinoma.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 27, 2024
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Braidwell LP
Deal Size : $165.0 million
Deal Type : Series C Financing
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
Details : The proceeds will be used to support the advancement of Bicara’s lead product, BCA101, a first-in-class bifunctional EGFR/TGF-β inhibitor, for multiple cancer types including frontline HPV-negative, R/M HNSCC, advanced squamous NSCLC and cutaneous squ...
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 12, 2023
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Braidwell LP
Deal Size : $165.0 million
Deal Type : Series C Financing
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Red Tree Venture Capital
Deal Size : $108.0 million
Deal Type : Series B Financing
Details : The Financing will support future studies of lead program BCA101, a first-in-class EGFR / TGF-β-trap bifunctional antibody, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 06, 2023
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Red Tree Venture Capital
Deal Size : $108.0 million
Deal Type : Series B Financing
Lead Product(s) : BCA356
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BCA356 specifically targets CAIX-expressing tumor cells, and similar to wild type IL-12 cytokine, has the potential to reduce tumor proliferation with optimal activation of additional pro-inflammatory cytokines.
Brand Name : BCA356
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 07, 2022
Lead Product(s) : BCA356
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BCA101 is a first-in-class antibody with a unique mechanism of anti-tumor activity that has demonstrated encouraging safety, pharmacokinetic, pharmacodynamic and efficacy profiles.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 03, 2022
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study will evaluate BCA101, EGFR / TGF-β-trap bifunctional antibody in patients with head and neck squamous cell carcinoma, squamous cell carcinoma of the anal canal and cutaneous squamous cell carcinoma.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2022
Lead Product(s) : BCA101,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : BCA101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Biocon
Deal Size : $40.0 million
Deal Type : Financing
Details : Bicara’s lead program, BCA101, a first-in-class EGFR / TGFβ-trap bifunctional antibody, entered a Phase 1/2 study at leading U.S. and Canadian cancer centers in July 2020.
Brand Name : BCA101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 15, 2021
Lead Product(s) : BCA101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Biocon
Deal Size : $40.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?